Short course of letrozole before surgery may reveal breast Cancer's hormone dependence

NCT ID NCT03747042

Completed Knowledge-focused Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial enrolled 61 postmenopausal women with operable, hormone-sensitive breast cancer. Participants took letrozole for 7 to 30 days before their scheduled surgery. The goal was to measure changes in a tumor marker called Ki67 to see which cancers are highly hormone-dependent. The study did not aim to treat the cancer directly but to gather information that could guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: letrozole
What this could lead to: If successful, this could help doctors identify which breast cancers are highly hormone-dependent and may respond best to letrozole treatment.
What could go wrong: This is a small, early-phase study with only 61 participants, and it measures a biomarker (Ki67) rather than long-term outcomes like survival or recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female breast carcinoma hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER FEMALE

Contacts and locations

Locations

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.